A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB

NCT01125800 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

76

Enrollment

INDUSTRY

Sponsor class

Conditions

Medulloblastoma
Rhabdomyosarcoma
Neuroblastoma
Hepatoblastoma
Glioma
Astrocytoma

Interventions

DRUG: LDE225

Sponsor

Novartis Pharmaceuticals